• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Canadian Journal of Neurological Sciences: le Journal Canadien des Sciences Neurologiques >P.005 Long-term retention on adjunctive brivaracetam in adults with focal seizures and previous carbamazepine, lamotrigine, levetiracetam, or topiramate use: Post-hoc analysis
【24h】

P.005 Long-term retention on adjunctive brivaracetam in adults with focal seizures and previous carbamazepine, lamotrigine, levetiracetam, or topiramate use: Post-hoc analysis

机译：P.005在成人患有焦点和以前的卡吡啶，乳草嗪，Levetiracetam或Topiramate使用的成人中的长期保留：HOC分析

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Previous post-hoc analysis of three 12-week, double-blind, placebo-controlled trials of adjunctive brivaracetam (BRV) in patients with focal seizures demonstrated similar efficacy over placebo regardless of previous carbamazepine (CBZ), lamotrigine (LTG), levetiracetam (LEV), or topiramate (TPM) failure. This analysis explored long-term retention of adjunctive BRV in patients with previous CBZ/LTG/LEV/TPM. Methods: Post-hoc analysis of double-blind, placebo-controlled trial (N01358 [NCT01261325]) and open-label extension (N01379 [NCT01339559]; cut-off 15-March-2017) of adjunctive BRV in patients (≥16 years) with focal seizures. Outcomes were assessed in patients randomized to BRV (100 or 200 mg/day) who had previous CBZ/LTG/LEV/TPM (stopped ≥90 days before BRV initiation). Results: 503 patients were analyzed. Baseline characteristics were generally similar in subgroups with previous CBZ/LTG/LEV/TPM (n=209/162/256/182). Overall, Kaplan-Meier-estimated BRV retention at 1-, 3-, and 5-years was 71.0%, 50.9%, and 32.4%. Across previous antiepileptic drug (AED) subgroups, Kaplan-Meier-estimated BRV retention (1-year: 64.8%–73.2%; 3-year: 41.9%–49.9%; 5-year: 31.5%–35.7%), BRV discontinuations (58.4%–63.0%), and most common reasons for discontinuation (lack of efficacy: 23.0%–25.3%; adverse event: 16.7%–22.2%) were generally similar. Conclusions: Post-hoc analysis demonstrated similar long-term retention rates and discontinuation reasons with adjunctive BRV in adults previously treated with CBZ/LTG/LEV/TPM. Adjunctive BRV provides long-term effectiveness in patients who failed common AED treatments, including LEV.UCB Pharma-sponsored
机译：背景：以前的31周后的HOC分析，临床癫痫发作患者的辅助BRIVARACETAM（BRV）的双盲，安慰剂对照试验表现出类似的疗效，无论先前的卡唑胺（CBZ），乳草嗪（LTG）， Levetiracetam（Lev）或Topiramate（TPM）失败。该分析探讨了先前CBZ / LTG / LEV / TPM患者的辅助BRV的长期保留。方法：双盲，安慰剂对照试验（N01358 [NCT01261325]）和开放标签延伸（N01379 [NCT01339559];患者的辅助BRV（≥16岁） ）焦点癫痫发作。在随机为BRV（100或200毫克/天）的患者中评估结果，患有先前CBZ / LTG / LEV / TPM（在BRV启动前停止≥90天）。结果：503例患者分析。基线特征在前一个CBZ / LTG / LEV / TPM的亚组中通常相似（n = 209/162 / 256/182）。总体而言，Kaplan-Meier估计的BRV保留为1-，3-和5年的留量为71.0％，50.9％和32.4％。在以前的抗癫痫药物（AED）亚组中，Kaplan-Meier估计的BRV保留（1年：64.8％-73.2％; 3年：41.9％-49.9％; 5年：31.5％-35.7％），BRV停止（58.4％-63.0％），并且停止的最常见原因（缺乏疗效：23.0％-25.3％;不良事件：16.7％-22.2％）普遍相似。结论：HOC分析表明，在先前用CBZ / LTG / LEV / TPM治疗的成人中的辅助BRV具有类似的长期保留率和中断原因。辅助BRV为普通患者的患者提供长期有效性，包括Lev.ucb Pharma-Suponsored

著录项

相似文献

  • 外文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号